Trial Profile
A Phase III, Open-label Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 23 Nov 2020 Results assessing patients status throughout REGAIN and its open label extension published in the Neurology
- 01 May 2020 Results of post-hoc pooled analysis of infection risk in patients receiving eculizumab in 4 studies (PREVENT (NCT01892345), REGAIN (NCT01997229), NCT02003144 and NCT02301624), presented at the 72nd Annual Meeting of the American Academy of Neurology.
- 12 Jul 2019 Status changed from active, no longer recruiting to completed.